Drug Trial Radar · NCT04848064
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
May 6, 2022
Primary completion
Jul 30, 2027
Study completion Jul 30, 2028
Sponsor
- Lead sponsor
- John ReneauAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving third-party natural killer cells in combination with mogamulizumab may kill more cancer cells.
Conditions
- Recurrent Adult T-Cell Leukemia/Lymphoma
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Refractory Adult T-Cell Leukemia/Lymphoma
- Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions
CyclophosphamideDrug
Given IV
FludarabineDrug
Given IV
MogamulizumabBiological
Given IV
Natural Killer Cell TherapyBiological
Given via infusion
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Up to day 84
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.